We aimed to focus on changes in lipid metabolism in CD4 + T-cells from patients with RRMS, which could drive dysregulated immune cell activation, differentiation, and function, and may contribute to MS pathogenesis and disease course [39]. The gene discussed is CD4; the disease is myeloid sarcoma.